The vein-to-vein finance problem
In an autologous cell therapy program, the patient is the starting material. A single batch produces a single dose for a single named individual. The chain of custody runs from apheresis at the treatment center, through transport, manufacturing, quality release, return shipment, and infusion. The clock matters at every step. The chain is auditable at every step. And finance has to recognize cost, value inventory, and recognize revenue against a product that is, by definition, never on the shelf.
Allogeneic programs change the chain but keep the complexity. Donor screening, master cell banks, batch failure rates that exceed anything small molecule manufacturers experience, and patient-level traceability that follows the dose from manufacture to administration. Generic ERP systems are not built for this. They assume inventory is a count and cost flows by average or standard.
NetSuite, configured for cell and gene therapy, handles the lot-of-one inventory model, the donor and patient identifiers required for chain of custody, the cost variance that comes with small batch manufacturing, and the revenue recognition model that runs against treatment milestones rather than shipment dates. Per Oracle NetSuite's Life Sciences documentation, integrated monitoring tracks batches, lots, and inventory from supplier to patient with full lot genealogy. Archer extends that foundation with the configuration that makes lot-of-one a workable financial model.
An autologous dose is not a SKU. It is a unique manufactured product tied to a specific patient. NetSuite has to treat the lot as the primary identifier.
Why generic ERP fails cell and gene therapy operators
Four configuration challenges are unique to CGT.
Lot-of-one inventory
An autologous dose is not a SKU. It is a unique manufactured product tied to a specific patient. NetSuite has to treat the lot as the primary identifier and link it to a patient or donor reference without storing protected health information directly in inventory records.
Chain of custody documentation
Every movement of a CGT product, from apheresis collection through final administration, has to be auditable. Time stamps, location, responsible party, and condition data have to live in the ERP transaction history, not in a separate logistics system.
Cost accounting on small batches
A CGT batch may produce 1 dose. Standard costing breaks down when the denominator is 1. Variance accounting has to differentiate between expected manufacturing variability and genuine process failure, because the financial implications and the regulatory implications are different.
Revenue recognition against treatment events
Some CGT contracts pay on shipment. Many pay on confirmed administration or on patient outcome milestones. ASC 606 application varies by contract structure, and the ERP has to support both.
How Archer configures NetSuite for cell and gene therapy
Archer treats the lot as the unit of inventory, the unit of cost, and the unit of revenue recognition. Item records carry the lot structure as the primary identifier. Patient and donor references are stored as encrypted custom fields on the lot record, with controlled access aligned to HIPAA and GDPR requirements. Chain of custody events post to the lot transaction history at every handoff, with 3PL Integration handling the apheresis center and treatment center handoffs.
Cost accounting uses actual costing at the lot level for autologous products. Raw materials, direct labor, and overhead are collected against the manufacturing order for the named patient. Batch failure is captured as a discrete event with a cost variance treatment that distinguishes recoverable from non-recoverable spend.
Revenue recognition is configured against the contract structure. Archer's Contract Lifecycle Management module tracks the obligations, milestones, and outcome triggers. Shipment-triggered recognition runs on the inventory fulfillment. Administration-triggered recognition runs against a confirmation event from the treatment center, integrated through NetSuite's REST capabilities.
For companies transitioning from IND to BLA, Archer configures the ERP to support the cost capitalization shift that comes with commercial-stage manufacturing. R and D expensing rules change. Inventory valuation becomes commercial. The configuration adjusts without rebuilding the system.
Related on archerinsights.com
- Cell and gene therapy industry page. Archer's NetSuite configuration for autologous and allogeneic programs.
- Biotech and pharmaceuticals industry page. Adjacent operating model for clinical-stage companies.
- Contract Lifecycle Management module. Outcome-based contract and milestone tracking.
- 3PL Integration. Chain of custody and treatment center handoff data flow.
- Quality Management System. Lot release workflows under GMP and Part 11 requirements.
- White papers and case studies. Written for life sciences finance leaders.
External references
- NetSuite Life Sciences ERP
- FDA 21 CFR Part 11: Electronic Records and Electronic Signatures
- ASC 606 Revenue Recognition Standard
- ICH Q5A/Q5D guidance on cell substrates
Configure NetSuite for the lot-of-one operating model
A discovery call with an Archer implementation lead covers the configuration gaps that matter most for autologous, allogeneic, or hybrid programs.